SA PRO
Free Account
Summit Therapeutics Inc.SMMTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 80% recommend buying.

Consensus Rating
Buy
20 analysts·High coverage
80%
Rating Distribution
Strong Buy
00%
Buy
1680%
Hold
420%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 99% higher.

Bear Case
$16.00
+12%
Consensus
$28.50
+99%
Bull Case
$40.00
+179%
Price Range20 analysts
Low
Consensus
High
$16.00
$40.00
Current Target
Current Price
$14.31
Upside to Target
$14.19

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 14, 2026Piper Sandler
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Target:$40.00
+136.8%from $16.89
Dec 17, 2025Summit Redstone Partners
Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight
Target:$18.00
+4.5%from $17.23
Oct 21, 2025H.C. Wainwright
Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright
Target:$40.00
+99.7%from $20.04
Oct 21, 2025Barclays
Summit Therapeutics price target raised to $16 from $13 at Barclays
Target:$16.00
-20.1%from $20.04
Sep 16, 2025Summit Redstone Partners
Summit Therapeutics initiated with an Underweight at Barclays
Target:$13.00
-28.3%from $18.12
Aug 19, 2025Summit Redstone Partners
Piper starts Summit Therapeutics with Neutral on high expectations
Target:$21.00
-18.3%from $25.71
Apr 28, 2025H.C. Wainwright
Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
Target:$44.00
+82.5%from $24.11
Apr 25, 2025Wells Fargo
Wells says Summit, Akeso data 'not the bull case,' but not 'bear case either'
Target:$30.00
+27.8%from $23.47
Apr 25, 2025Jefferies
Jefferies uncovers China approval for Summit Therapeutics, ups target
Target:$44.00
+71.8%from $25.61
Mar 26, 2025Summit Redstone Partners
Summit Therapeutics upgraded to Buy from Neutral at Citi
Target:$35.00
+76.0%from $19.89
Feb 28, 2025Summit Redstone Partners
Goldman starts Summit Therapeutics with a Buy on ivonescimab potential
Target:$42.00
+103.0%from $20.69
Nov 4, 2024JMP Securities
JMP Securities Starts Summit Therapeutics plc (SMMT) at Market Outperform
Target:$32.00
+60.3%from $19.96
Sep 27, 2024Summit Redstone Partners
Citi Downgrades Summit Therapeutics plc (SMMT) to Neutral, 'Valuation Looking Fair for Now'
Target:$23.00
+10.1%from $20.89
Sep 25, 2024Stifel Nicolaus
Summit Therapeutics plc (SMMT) PT Raised to $40 at Stifel
Target:$40.00
+66.7%from $24.00
Sep 16, 2024H.C. Wainwright
Summit Therapeutics price target raised to $45 from $30 at H.C. Wainwright
Target:$45.00
+40.9%from $31.93
Jun 3, 2024Stifel Nicolaus
Summit Therapeutics plc (SMMT) PT Raised to $14 at Stifel
Target:$14.00
+61.2%from $8.69
Mar 25, 2024Stifel Nicolaus
Stifel Starts Summit Therapeutics plc (SMMT) at Buy, 'ivonescimab has high probability-of-success'
Target:$8.00
+143.9%from $3.28

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance